Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | KDM3B | Q7LBC6 | 1/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | F7 | P08709 | 1/20 | 0.36 |
| ▸ | F3 | P13726 | 1/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7116182 | 0.85 | CCNC (0.47) | NOTUMCSNK2A1CSNK2A2CSNK2BKDM4E | |
| SCHEMBL16416410 | 0.82 | CSNK2A1 (0.36) | NOTUMCSNK2A1CSNK2A2CSNK2BKDM4E | |
| SCHEMBL6022280 | 0.82 | NR4A2 (0.45) | GRM1 | |
| SCHEMBL6022276 | 0.82 | NR4A2 (0.41) | NOTUMTSHRGRM1 | |
| SCHEMBL10937546 | 0.79 | AKR1C3 (0.48) | KDM4ETSHR | |
| SCHEMBL10090785 | 0.79 | GRM1 (0.53) | KDM4EMEN1KMT2ATSHRGRM1 | |
| SCHEMBL10942984 | 0.79 | AKR1C3 (0.48) | KDM4E | |
| SCHEMBL12529489 | 0.79 | GRM1 (0.53) | KDM4EMEN1KMT2ATSHRGRM1 | |
| SCHEMBL9748278 | 0.79 | NOTUM (0.50) | NOTUMCSNK2A1CSNK2A2CSNK2BKDM4E | |
| SCHEMBL547358 | 0.79 | NOTUM (0.50) | NOTUMCSNK2A1CSNK2A2CSNK2BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121324559-A | Application of metabonomics marker combination in preparation of product for identifying benign and malignant pulmonary glass nodule | 中国人民解放军总医院第八医学中心 | 2026-01-13 | — | — | CN | disclosed |
| CN-119827684-A | Beijing white pear origin identification method based on metabonomics technology | 北京市农林科学院 | 2025-04-15 | — | — | CN | disclosed |
| EP-2438078-B1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | UNIV KANSAS (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9120774-B2 | Novobiocin analogues having modified sugar moieties | UNIVERSITY OF KANSAS (US) | 2015-09-01 | — | — | US | disclosed |
| US-8212011-B2 | Novobiocin analogues | UNIVERSITY OF KANSAS (US) | 2012-07-03 | — | — | US | disclosed |
| US-8212011-B2 | Novobiocin analogues | UNIVERSITY OF KANSAS (US) | 2012-07-03 | — | — | US | disclosed |
| US-8212012-B2 | Novobiocin analogues having modified sugar moieties | UNIVERSITY OF KANSAS (US) | 2012-07-03 | — | — | US | disclosed |
| US-8212012-B2 | Novobiocin analogues having modified sugar moieties | UNIVERSITY OF KANSAS (US) | 2012-07-03 | — | — | US | disclosed |
| US-7960353-B2 | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders | UNIVERSITY OF KANSAS (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960353-B2 | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders | UNIVERSITY OF KANSAS (US) | 2011-06-14 | — | — | US | disclosed |
| US-20070043053-A1 | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-02-22 | — | — | US | disclosed |
| US-7160883-B2 | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | BRISTOL-MYERS-SQUIBB COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| US-7034151-B2 | 1,4-dihydro-4-oxo-pyrrolo[2,1-f][1,2,4]triazine-6-carboxylates; novel approach to the formation of the bicyclic heterocyclic ring system | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-25 | — | — | US | disclosed |
| EP-1590335-A4 | PROCESS FOR PREPARING PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20060041124-A1 | Process for preparing pyrrolotriazine kinase inhibitors | CHEN BANG-CHI | 2006-02-23 | — | — | US | disclosed |
| EP-1590335-A2 | PROCESS FOR PREPARING PYRROLOTRIAZINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20050064563-A1 | Nucleic acids for aminocoumarin biosynthesis | UNIVERSITAT TUBINGEN (DE) | 2005-03-24 | — | — | US | disclosed |
| WO-2004072030-A2 | PROCESS FOR PREPARING PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-26 | — | — | WO | disclosed |
| US-20040157846-A1 | Process for preparing pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-12 | — | — | US | disclosed |
| US-4473394-A | HERBICIDES | E. I. DUPONT DE NEMOURS & COMPANY (US) | 1984-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043053-A1 | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | PLK2, CDK2, MAP3K15 | NOTUM 2516/4885CSNK2A1 146/4885CSNK2A2 182/4885 |
| US-20040157846-A1 | Process for preparing pyrrolotriazine kinase inhibitors | MAP3K15, MAP4K2, MAP3K5 | NOTUM 2691/4885CSNK2A1 280/4885CSNK2A2 268/4885 |
| US-20060041124-A1 | Process for preparing pyrrolotriazine kinase inhibitors | MAP3K15, MAP4K2, MAP3K5 | NOTUM 2691/4885CSNK2A1 280/4885CSNK2A2 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.